Insugen-R 40IU/ml Solution for Injection contains human insulin at a concentration of 40 international units per milliliter, indicated for the management of diabetes mellitus requiring insulin therapy. This rapid-acting insulin formulation is designed to facilitate glycemic control by promoting cellular glucose uptake and inhibiting hepatic glucose production. Insugen-R is suitable for subcutaneous administration and may be used in insulin pumps or by intravenous injection under medical supervision. The onset of action typically occurs within 15 minutes, with peak effects observed between 30 to 90 minutes and a duration of action lasting approximately 4 to 6 hours, allowing for effective postprandial glucose regulation. It is essential to individualize dosing based on patient-specific factors including blood glucose monitoring results, dietary intake, and physical activity levels. Caution is advised to avoid hypoglycemia, the most common adverse effect, which may present with symptoms such as sweating, dizziness, and palpitations. Insugen-R should be stored under refrigeration between 2°C to 8°C and protected from light. Prior to administration, the solution should be inspected for particulate matter or discoloration; any compromised vials must be discarded. This product is contraindicated in patients with hypoglycemia or known hypersensitivity to human insulin or any excipients. Proper patient education on injection technique and dose adjustment is critical to optimize therapeutic outcomes.